Literature DB >> 1461380

A clinical staging classification for type C Niemann-Pick disease.

J J Higgins1, M C Patterson, J M Dambrosia, A T Pikus, P G Pentchev, S Sato, R O Brady, N W Barton.   

Abstract

Analysis of the temporal sequence of neurologic events, neurophysiologic abnormalities, and longevity in 36 Niemann-Pick type C patients revealed two clinical subgroups with five stages of severity within each group. Patients with a preschool onset (group I; n = 18) had a higher mortality than did patients with a school-age onset (group II; n = 18). An asymptomatic phase (stage 0) was defined by biochemical and histopathologic evidence of disease. The initial manifestations of stage 1 were a movement disorder (group I) and cognitive difficulties (group II) accompanied by impaired vertical saccadic eye movements and abnormal acoustic reflexes. Stage 2 was characterized by the sequential occurrence of vertical supranuclear gaze palsy (VSGP), cognitive difficulties, and dysarthria in group I and a movement disorder, VSGP, and dysarthria in group II. Pyramidal tract signs and abnormal brainstem auditory evoked responses defined stage 3 in both groups. Stage 4 culminated in a nonambulant, vegetative state.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1461380     DOI: 10.1212/wnl.42.12.2286

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

Review 1.  Brain stem evoked potentials in childhood neurological diseases.

Authors:  R Kalmanchey
Journal:  Indian J Pediatr       Date:  1997 Sep-Oct       Impact factor: 1.967

2.  Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C.

Authors:  Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

3.  Feline Niemann-Pick disease type C.

Authors:  D E Brown; M A Thrall; S U Walkley; D A Wenger; T W Mitchell; M O Smith; K L Royals; P A March; R W Allison
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

4.  Nerve biopsy findings in Niemann-Pick type II (NPC)

Authors:  A F Hahn; J J Gilbert; C Kwarciak; J Gillett; C F Bolton; C A Rupar; J W Callahan
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

5.  Ryanodine receptor antagonists adapt NPC1 proteostasis to ameliorate lipid storage in Niemann-Pick type C disease fibroblasts.

Authors:  Ting Yu; Chan Chung; Dongbiao Shen; Haoxing Xu; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2012-04-14       Impact factor: 6.150

6.  Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis.

Authors:  Chris D Pacheco; Matthew J Elrick; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

7.  Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration.

Authors:  Matthew J Elrick; Chris D Pacheco; Ting Yu; Nahid Dadgar; Vikram G Shakkottai; Christopher Ware; Henry L Paulson; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2009-12-10       Impact factor: 6.150

8.  [Niemann-Pick disease type C--a neurometabolic disease through disturbed intracellular lipid transport].

Authors:  A J Grau; M Weisbrod; E Hund; K Harzer
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

9.  Linkage of Niemann-Pick disease type D to the same region of human chromosome 18 as Niemann-Pick disease type C.

Authors:  W L Greer; D C Riddell; D M Byers; J P Welch; G S Girouard; S M Sparrow; T L Gillan; P E Neumann
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

Review 10.  The pathogenesis of Niemann-Pick type C disease: a role for autophagy?

Authors:  Chris D Pacheco; Andrew P Lieberman
Journal:  Expert Rev Mol Med       Date:  2008-09-10       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.